PharmTech Talk - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PharmTech Talk

Europe Hones in on Antitrust Violations

September 2, 2012

Pharmaceutical Technology

The European Commission remains vigilant in monitoring potential pay-to-delay deals.

Healthcare Reform is Given the Go-Ahead: Now What?

August 2, 2012

Pharmaceutical Technology

No matter the upside or downside to the Affordable Care Act, there's work to be done.

Hot-Melt Developments

July 2, 2012

Pharmaceutical Technology

Developments in hot-melt extrusion using twin-screw extruders to make solid-dosage drug forms.

Cheap versus Expensive

June 2, 2012

Pharmaceutical Technology

UK chooses to use off-label drug indication to cut healthcare costs. Will others follow suit?

Tackling Global Health Concerns

May 2, 2012

Pharmaceutical Technology

Industry, the public sector, and individuals can play an important role in creating solutions.

PDA Tackles Changing Industry Times

April 2, 2012

Pharmaceutical Technology

The confluence of science, technology, and regulation can provide path forward.

FDA Encourages Whistleblowers, Just Not Its Own

March 2, 2012

Pharmaceutical Technology

FDA's treatment of whistleblowers lacks internal consistency.

FDA's Social Media Insight

February 2, 2012

Pharmaceutical Technology

Guidance offered on how to deal with off-label information requests.

Cutting Prices to Save Sales

January 2, 2012

Pharmaceutical Technology

Copay coupons may help patients and drugmakers, but who ends up holding the bag?

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
15%
Protecting the supply chain
46%
Expedited reviews of drug submissions
8%
More stakeholder involvement
0%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Click here